Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

20211,318 citationsJournal Articlehybrid Open Access

Authors

Shabir A. Madhi · South African Medical Research Council

Vicky L. Baillie · South African Medical Research Council

Clare Cutland · MACOM (United States)

Merryn Voysey · MACOM (United States)

Anthonet Koen · South African Medical Research Council

Lee Fairlie · MACOM (United States)

Sherman D. Padayachee

Abstract

A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132).

Topics & Keywords

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies Retinal and Optic Conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 20, pp. 1885-1898

DOI: 10.1056/nejmoa2102214

Field-Weighted Citation Impact: 82.93